A Director at Recro Pharma is Exercising Options

By Carrie Williams

Today, a Director at Recro Pharma, Michael Berelowitz, exercised options of Recro Pharma for $78.3K.

This is Berelowitz’s first transaction since reporting a Sell transaction on ORMP back in December 2015

Based on Recro Pharma’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $19.04 million and GAAP net loss of $24.08 million. In comparison, last year the company earned revenue of $17.36 million and had a GAAP net loss of $10.4 million. The company has a one-year high of $11.57 and a one-year low of $5.81. Currently, Recro Pharma has an average volume of 570.3K.

The insider sentiment on Recro Pharma has been negative according to 35 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Recro Pharma, Inc. is a pharmaceutical company, whcih is focused on products for hospitals and ambulatory care settings. The company is developing non-opioid products for treatment of serious acute pain. It offers drug solutions for cancer, musculoskeletal disorders and peripheral neuropathy, cancer breakthrough and acute post-operative pain.